Outset Medical, Inc. to Announce Third Quarter 2025 Financial Results on November 10, 2025

Outset Medical will publish Q3 2025 financial results on November 10, followed by a conference call with executives.

Quiver AI Summary

Outset Medical, Inc. has announced the release of its financial results for the third quarter of 2025, which will take place after market close on November 10, 2025. Following this release, CEO Leslie Trigg and CFO Renee Gaeta will host a conference call at 1:30 p.m. Pacific time to discuss the results, and interested participants can register online for access. Outset Medical is known for its innovative Tablo® Hemodialysis System, which simplifies dialysis by integrating water purification and dialysate production into a single system that connects with electronic medical records, enhancing operational and clinical outcomes for healthcare providers.

Potential Positives

Outset Medical is set to release its third quarter 2025 financial results, indicating transparency and commitment to keeping investors informed.
The upcoming conference call will be hosted by key executives, showcasing leadership engagement and providing an opportunity for direct communication with stakeholders.
The Tablo® Hemodialysis System is being utilized by over 1,000 U.S. healthcare facilities, highlighting the company's market penetration and trust within the healthcare community.
Outset's technology aims to significantly reduce costs and complexity in dialysis, which could lead to improved operational efficiencies and better outcomes for patients and providers.

Potential Negatives

The press release lacks specific details regarding the financial results for Q3 2025, leaving investors without clear expectations for performance.
There is a risk of negative market perception if the financial results discussed on the upcoming call do not meet investor expectations.
The announcement does not provide new data or insights about the market acceptance or performance of their key product, the Tablo® Hemodialysis System, which may raise concerns about its growth potential.

FAQ

When will Outset Medical release its Q3 2025 financial results?

Outset Medical will release its Q3 2025 financial results on November 10, 2025, after market close.

Who will host the financial results conference call?

Leslie Trigg, CEO, and Renee Gaeta, CFO, will host the conference call to discuss the financial results.

What time does the conference call start?

The conference call will begin at 1:30 p.m. Pacific time on November 10, 2025.

How can I participate in the conference call?

Participants can register online to receive dial-in numbers and a unique pin for the conference call.

Where can I find the webcast of the event?

A live and archived webcast will be available in the “Investors” section of the Outset website.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$OM Insider Trading Activity

$OM insiders have traded $OM stock on the open market 7 times in the past 6 months. Of those trades, 0 have been purchases and 7 have been sales.

Here’s a breakdown of recent trading of $OM stock by insiders over the last 6 months:

LESLIE TRIGG (Chair and CEO) has made 0 purchases and 2 sales selling 1,839 shares for an estimated $28,286.
JOHN L. BROTTEM (General Counsel) has made 0 purchases and 2 sales selling 779 shares for an estimated $11,989.
NABEEL AHMED (Chief Financial Officer) sold 584 shares for an estimated $10,401
MARC NASH (SVP Operations and R&D) has made 0 purchases and 2 sales selling 495 shares for an estimated $7,620.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$OM Hedge Fund Activity

We have seen 2 institutional investors add shares of $OM stock to their portfolio, and 1 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

NISA INVESTMENT ADVISORS, LLC removed 410 shares (-85.1%) from their portfolio in Q3 2025, for an estimated $5,789
OSAIC HOLDINGS, INC. added 366 shares (+inf%) to their portfolio in Q2 2025, for an estimated $7,030
ACCENT CAPITAL MANAGEMENT, LLC added 150 shares (+inf%) to their portfolio in Q2 2025, for an estimated $2,881

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

Full Release

SAN JOSE, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the third quarter 2025 after the close of trading on Monday, November 10, 2025.

On the same day, at 1:30 p.m. Pacific time (4:30 p.m. Eastern time), Leslie Trigg, Chair and Chief Executive Officer, and Renee Gaeta, Chief Financial Officer, will host a conference call to discuss financial and operating results.

Conference Call Details
The conference call will begin at 1:30 p.m. Pacific time (4:30 p.m. Eastern time) on Monday, November 10, 2025. Those interested in joining the conference call may do so by registering online . Once registered, participants will receive dial-in numbers and a unique pin to join the call. Participants are encouraged to register more than 15 minutes before the start of the call. A live and archived webcast of the event will be available on the “Investors” section of the Outset website at https://investors.outsetmedical.com/ .

About Outset Medical, Inc.
Outset is a medical technology company transforming the dialysis experience across the continuum of care with a first-of-its-kind technology. The Tablo® Hemodialysis System, FDA-cleared for use from hospital to home, is trusted by more than 1,000 U.S. healthcare facilities and has enabled millions of treatments delivered by thousands of nurses. Designed to reduce the cost and complexity of dialysis, Tablo combines water purification and on-demand dialysate production into a single, integrated system that connects seamlessly with Electronic Medical Record systems and a proprietary data analytics platform. This enterprise solution empowers providers to develop an in-house dialysis program where they are in control – enabling better operational, clinical, and financial outcomes. Outset is redefining what’s possible in kidney care through innovation, scale, and a relentless commitment to improving the lives of patients and the professionals who care for them. For more information, visit www.outsetmedical.com .

Contact
Jim Mazzola
[email protected]